Trimetazidine in the myocardial cell mechanisms of cytoprotection.
The experimental results demonstrate that TMZ displays the pharmacological characteristics of a "cytoprotective agent", since this drug exerts an anti-ischemic effect on myocardium totally independent of any hemodynamic changes.
Labrid
C
C
Servier International, Courbevoie, France.
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004734:Energy Metabolism / Q000187:drug effects; D006321:Heart / Q000187:drug effects*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D014292:Trimetazidine / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D014665:Vasodilator Agents; D014292:Trimetazidine